

Aisha Elsharkawy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11942896/publications.pdf>

Version: 2024-02-01

55
papers

4,146
citations

361413

20
h-index

175258

52
g-index

55
all docs

55
docs citations

55
times ranked

7516
citing authors

#	ARTICLE	IF	CITATIONS
1	The oral microbiome of treated and untreated chronic HCV infection: A preliminary study. <i>Oral Diseases</i> , 2023, 29, 843-852.	3.0	2
2	HCV/HIV coinfecting Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 227-232.	1.8	3
3	Perceived stigma and healthcare services in healthcare settings among people living with HIV in Egypt: a qualitative study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 868-873.	1.8	0
4	Highly Sensitive Serum miRNA Panel for the Diagnosis of Hepatocellular Carcinoma in Egyptian Patients with HCV-Related HCC. <i>Laboratory Medicine</i> , 2022, 53, 523-529.	1.2	3
5	Fibrosis regression following hepatitis C antiviral therapy. <i>World Journal of Hepatology</i> , 2022, 14, 1120-1130.	2.0	5
6	Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. <i>Platelets</i> , 2021, 32, 383-390.	2.3	5
7	Evaluation of red cell distribution width to platelet ratio as a novel non-invasive index for predicting hepatic fibrosis in patients with chronic hepatitis C. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 6-11.	0.9	1
8	Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. <i>Lancet HIV</i> , 2021, 8, e363-e375.	4.7	32
9	Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	1.6	1
10	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV</i> , 2021, 8, e633-e651.	4.7	56
11	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. <i>Nature Medicine</i> , 2021, 27, 1761-1782.	30.7	60
12	OUP accepted manuscript. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, , .	1.8	0
13	Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.6	0
14	Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1008-1016.	1.6	19
15	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	6.3	23
16	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	6.3	91
17	Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. <i>Infection</i> , 2020, 48, 913-922.	4.7	2
18	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , 2020, 395, 1779-1801.	13.7	72

#	ARTICLE	IF	CITATIONS
19	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. <i>New England Journal of Medicine</i> , 2020, 382, 1166-1174.	27.0	160
20	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	8.1	823
21	Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 637-642.	4.4	13
22	Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 232-240.	1.8	5
23	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1009-1016.	3.0	5
24	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , 2019, 6, e831-e859.	4.7	341
25	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	7.1	1,691
26	DAA's therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 693-698.	3.0	8
27	Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. <i>Abdominal Radiology</i> , 2019, 44, 2751-2758.	2.1	12
28	Clinical impact of serum Î±-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1129-1134.	1.6	13
29	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. <i>Gut</i> , 2019, 68, 721-728.	12.1	34
30	Genetic Variants in Nicotinamide-N-Methyltransferase (NNMT) Gene are Related to the Stage of Non-Alcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter (CAP)-FibroScan. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 27, 265-272.	0.9	7
31	Comparing the efficiency of Fibâ€“4, Egyâ€“score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1106-1111.	5.0	13
32	HCV in Egypt, prevention, treatment and key barriers to elimination. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 345-350.	4.4	43
33	Novel scores combining AFP with nonâ€“invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2018, 90, 1080-1086.	5.0	18
34	Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 129-136.	1.2	13
35	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. <i>Journal of Hepatology</i> , 2018, 68, 691-698.	3.7	50
36	Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. <i>Hepatology International</i> , 2018, 12, 75-82.	4.2	24

#	ARTICLE	IF	CITATIONS
37	Interferon gamma and interleukin 8 gene polymorphisms in patients with hepatitis C virus related oral lichen planus. Archives of Oral Biology, 2018, 96, 189-194.	1.8	15
38	High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. European Journal of Gastroenterology and Hepatology, 2018, 30, 1194-1199.	1.6	7
39	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. European Journal of Gastroenterology and Hepatology, 2018, 30, 882-887.	1.6	6
40	Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1624-1630.	2.8	71
41	Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Review of Gastroenterology and Hepatology, 2017, 11, 773-778.	3.0	27
42	miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. Infection, Genetics and Evolution, 2017, 51, 173-181.	2.3	32
43	Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. Acta Tropica, 2017, 176, 283-287.	2.0	6
44	Improvement of glycemic state among responders to Sofosbuvir based treatment regimens: Single center experience. Journal of Medical Virology, 2017, 89, 2181-2187.	5.0	39
45	Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients. Arab Journal of Gastroenterology, 2017, 18, 210-215.	0.9	3
46	Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 17-25.	2.5	129
47	Assessment of hepatic fibrosis by fibroscan in egyptian chronic hemodialysis patients with chronic Hepatitis C (genotype 4): A single-center study. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28, 764-773.	0.3	3
48	FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology, 2016, 17, 78-83.	0.9	25
49	IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy. Journal of Interferon and Cytokine Research, 2015, 35, 649-653.	1.2	5
50	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. Journal of Interferon and Cytokine Research, 2015, 35, 49-54.	1.2	37
51	Value of E/S core in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase to platelet ratio index, FIB and F orns' index in chronic hepatitis C virus. Hepatology Research, 2015, 45, 560-570.	3.4	17
52	Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: A preliminary approach. Saudi Journal of Gastroenterology, 2014, 20, 170.	1.1	4
53	Fibroscan of chronic HCV patients coinfecting with schistosomiasis. Arab Journal of Gastroenterology, 2013, 14, 109-112.	0.9	20
54	Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. Arab Journal of Gastroenterology, 2013, 14, 94-98.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response. World Journal of Gastroenterology, 2013, 19, 2691.	3.3	39